active
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just get another alias... that's what everybody else has been doing.
Great research as always Gcbr.
CLOSE .10
Iwant2be, you said,
They are penguins selling ice.
that is a classic... thanks
Go to sleep ann441j... I am
AMEN mikenickels, appreciate the imput.
Thanks wantahummer2, I will go to Amazon.com and check it out.
Thanks for saying that, my sister is of the same opinion... I will get some.
I actually take Apple Cider vinegar & Garlique with 25 minutes of bike riding 3 times a week. Blood pressure 128/85 and no cholesterol to mention.... now if someone can find a cure for arthritis?
Oops spoke to fast....
RB back up...
SWEET
Thanks Gcbr... misery loves co...
RB is wacky in the last hour on my computer no matter which browser I use... anyone else having any problems?
You're OK ann... my prayers are with you and your family.
OT: Having problems with the cable on the south side of town.. well here in Morrow anyway. I called the cable Co. about the problem around 6 p.m. I found out around 11 p.m. after calling a friend complaining about not being able to get on the internet and he asked was the tv working... and I turned it on and snow - it was off... tv or internet... INTERNET PLEASE!
Good morning ann441j.... good morning Miss Scarlet!
OT: Easyman51-You should read a litte further you would see this applies to the Wild Beast in the revelations who will control you because of the mark 6-6-6....... not a slam just a litte enlightment this a.m.
I like the article Blue.... thanks!
cosmiclifeform I'm under the impression that you do more research than those writers.
You are quite welcome.
In Atlanta... well a little south of Miss Scarlet about 15-20 miles.
I'm not sleep ann441j...
DNAG making the right moves... takes time to build Rome.
TOOOOOOOOOOOOOOOO PROFIT... DUHHHHHHHH
I can't imagine why anyone would hang around a penny stock message board trashing a stock they don't believe in.
Thanks to both of you.
OT: Strange market this co. DNA released great news and the stock drops??? Even CNBC had a great segment on this news!
Press Release Source: Genentech, Inc.
Phase III Study Shows Lucentis(TM) Improved Vision in Patients With Wet Age-Related Macular Degeneration
Monday July 18, 12:40 pm ET
MONTREAL, July 18 /PRNewswire-FirstCall/ -- Genentech, Inc. (NYSE: DNA - News) announced today positive results from the Phase III MARINA study of the investigational anti-VEGF drug Lucentis(TM) (ranibizumab) in 716 patients with wet age-related macular degeneration (AMD). In addition to meeting the study's primary efficacy endpoint of maintaining vision in patients with wet AMD, secondary endpoint results show there was a 17 letter difference in mean change in visual acuity from study entry between patients treated with Lucentis (regardless of 0.3 mg or 0.5 mg dose) and those in the control group, as measured by the Early Treatment of Diabetic Retinopathy (ETDRS) eye chart. At 12 months, patients treated with Lucentis gained an average of seven letters in visual acuity compared to study entry, while those in the control group lost an average of 10.5 letters. One-year data from the study were presented today during the 23rd Annual Meeting of the American Society of Retina Specialists (ASRS) in Montreal, Canada.
ADVERTISEMENT
"These data are very compelling because, for the first time, we have a potential treatment which has been shown to improve vision in a significant number of patients with wet AMD as opposed to just slowing progression of vision loss," said Joan W. Miller, M.D., retina specialist at the Massachusetts Eye and Ear Infirmary who presented the data today.
An analysis of the one-year data showed that adverse events were similar to those seen in earlier trials of Lucentis. Common side effects occurring more frequently in the Lucentis arms than in the control group were mild to moderate and included conjunctival hemorrhage, eye pain and vitreous floaters. Serious ocular adverse events occurring more frequently in Lucentis-treated patients were uncommon (<1 percent) and included uveitis and endophthalmitis. There appeared to be no imbalance in serious non-ocular adverse events.
Additional key study findings include:
-- 95 percent (452/478) of Lucentis-treated patients lost fewer than 15 letters compared to baseline, the primary endpoint of the study, compared with 62 percent (148/238) for the sham injection control group.
-- 25 percent (59/238) of patients treated with 0.3 mg of Lucentis and 34 percent (81/240) treated with 0.5 mg of Lucentis improved vision by a gain of 15 letters or more compared to approximately 5 percent (11/238) of patients in the control group.
-- Nearly 40 percent (188/478) of Lucentis-treated patients achieved a visual acuity score of 20/40 or better at 12 months compared to 11 percent (26/238) in the control group.
"We are very excited that Lucentis has improved vision in patients with wet AMD and look forward to results of a second Phase III trial," said Hal Barron, M.D., Genentech senior vice president, development and chief medical officer. "The magnitude of the treatment effect in this study suggests that Lucentis could have a major impact on the lives of patients with wet AMD."
Lucentis is a humanized antibody fragment developed at Genentech and designed to bind and inhibit Vascular Endothelial Growth Factor A (VEGF-A), a protein that is believed to play a critical role in angiogenesis (the formation of new blood vessels). Earlier this month, Genentech announced it has requested a fast-track designation for the Lucentis development program in wet AMD. If granted by the U.S. Food and Drug Administration (FDA), this could enable Genentech to begin a rolling Biologics License Application filing by the end of 2005.
About the Study
Minimally classic/occult trial of the Anti-VEGF antibody Ranibizumab (formerly, RhuFab) In the treatment of Neovascular AMD (MARINA) is a Phase III study of 716 patients in the United States with minimally classic or occult wet AMD who were randomized 2:1 to receive intravitreal Lucentis injections or a control regimen. The control regimen consisted of a sham injection, meaning the treating physician prepares and anesthetizes the patient's eye but does not perform an injection. Patients treated with Lucentis were further randomized to receive either a 0.3 mg or 0.5 mg dose of Lucentis once a month for two years.
Exclusion criteria included prior subfoveal laser treatment, verteporfin photodynamic therapy (PDT) or experimental treatments for wet AMD. Patients participating in the MARINA study could receive PDT therapy if they converted to predominantly classic disease while on the study or if they had small, active minimally classic or occult lesions and lost 20 letters or more in visual acuity on two consecutive physician evaluations. As a result, 11 percent (25/238) of patients in the control group, 0.4 percent (1/238) of patients in the Lucentis 0.3 mg group and no patients in the 0.5 mg group received PDT in the first year of study.
Ongoing Phase III Studies
Genentech and Novartis Pharma AG are conducting an additional Phase III study of Lucentis, ANCHOR (ANti-VEGF Antibody for the Treatment of Predominantly Classic CHORoidal Neovascularization in AMD). This is a randomized, multi-center, double-masked, active treatment controlled study comparing two different doses of Lucentis to PDT in 423 patients. The trial is ongoing in the United States, Europe and Australia in patients with predominantly classic wet AMD. Results from this study are expected in the fourth quarter of 2005.
Genentech is conducting an additional Phase IIIb study, PIER (A Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization with or without Classic CNV Secondary to Age-Related Macular Degeneration), a randomized, double-masked, sham injection-controlled study comparing one of two doses of Lucentis to sham injections in 184 patients in the United States with wet AMD. In this trial, Lucentis is administered once per month for the first three doses followed thereafter by doses once every three months for two years. Results from this study are expected in the first quarter of 2006.
Genentech recently began enrollment in the HORIZON Phase III open-label extension study, which allows eligible patients who have completed participation in certain other Lucentis clinical studies to continue to receive the investigational drug.
About Lucentis
Lucentis(TM) (ranibizumab) is a humanized therapeutic antibody fragment developed at Genentech and designed to bind and inhibit VEGF-A, a protein that is believed to play a critical role in angiogenesis (the formation of new blood vessels). Lucentis is designed to block new blood vessel growth and leakiness, which lead to wet AMD disease progression and vision loss. Lucentis is being developed by Genentech and the Novartis Ophthalmics Business Unit. Genentech retains commercial rights for Lucentis in North America (United States, Canada and Mexico). Novartis has exclusive commercialization rights for the rest of the world.
About AMD
AMD is a major cause of painless central visual loss and is the leading cause of blindness for people over the age of 60 in the United States and Canada. The National Eye Institute estimates that there are 1.6 million people with AMD in the United States alone and that this prevalence will grow to 2.95 million by 2020. In Canada, the Foundation Fighting Blindness estimates that more than 800,000 people are affected by the disease.
AMD occurs in two forms: dry and wet. The dry form is associated with atrophic cell death of the central retina or macula, which is required for fine vision used for activities such as reading, driving or recognizing faces. The wet form is caused by growth of abnormal blood vessels also known as choroidal neovascularization (CNV) or ocular angiogenesis under the macula. These vessels leak fluid and blood and cause scar tissue that destroys the central retina. This results in a deterioration of sight over a period of months to years.
About Angiogenesis
Genentech is a leader in research and product development in the area of angiogenesis, the process by which new blood vessels are formed. In 1989, Napoleone Ferrara, M.D., and a team of scientists at Genentech conducted seminal work in the field, which resulted in the identification and cloning of a gene termed Vascular Endothelial Growth Factor (VEGF), now known as VEGF-A. The VEGF-A protein is believed to play a critical role in angiogenesis and serves as one of the key contributors to physiological or pathological conditions that can stimulate the formation of new blood vessels. The process of angiogenesis is normally regulated throughout development and adult life, and the uncontrolled growth of new blood vessels is an important contributor to a number of pathologic conditions, including wet AMD.
About Genentech
Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from, or are based on, Genentech science. Genentech manufactures and commercializes multiple biotechnology products directly in the United States and licenses several additional products to other companies. The company has headquarters in South San Francisco, Calif., and is traded on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit www.gene.com.
This press release contains forward-looking statements regarding the expected time frame for results from the Phase III ANCHOR and PIER trials and for filing a Biologics License Application (BLA) for Lucentis, and actual results could differ materially. Among other things, the timing of the trial results could be affected by additional time requirements for data analysis or discussions with the FDA, and the timing for the BLA filing could be affected by all of the foregoing and by additional time requirements for BLA preparation, need for additional clinical studies, or FDA actions or delays.
Media Contact: Dawn Kalmar 650-225-5873
Investor Contact: Kathee Littrell 650-225-1034
Source: Genentech, Inc.
I've put one person in my life on ignore and it's that person.
Blue try this link: http://www.dnaprint.com/pipeline.html
Thanks samlion that one works.
Thanks stakddek it workd... I emailed the link & info to few people.
That link isn't working for me stakddek... you think something is wrong with my browser?
Great stuff stakddek... just what the doctor ordered.
ann441j Coffee hhhmmmmmmmmm... actually I don't drink the stuff. Miss Scarlet probably has a assortment of refreshments. Lemonade being my favorite...
Press Release Source: SmarTire Systems Inc.
Louis To Distribute SmarTire For Motorcycles
Monday July 18, 9:30 am ET
OTCBB: SMTR
RICHMOND, BC, July 18 /CNW/ - SmarTire Systems Inc. (OTC Bulletin Board: SMTR - News) announced today that Detlev Louis Motorradvertriebs GmbH in Hamburg, Germany, the largest mail order company for motorcycle garments and technical parts in Europe, will be distributing SmarTire for Motorcycles.
SmarTire for Motorcycles is an active tire pressure and temperature monitoring system that provides real-time tire information to the rider while the bike is in motion. At a push of the button, SmarTire displays each tire's pressure, temperature and pressure deviation. If the system detects a loss of air pressure or abnormally high tire temperature, a bright warning light automatically alerts the rider to the condition.
Al Kozak, President & CEO of SmarTire, said, "We are pleased to add Louis GmbH as a new distributor in the European market. Louis is one of the most respected sources of quality accessories for motorcycles in Europe and will begin to market our product in July of this year. Louis is the market leader for motorcycle garments and accessories with 55 shops in Germany and four in Austria."
About Detlev Louis Motorradvertriebs GmbH
Louis' success has been based on the 880-page catalogue. The company produces 1.1 million copies per year. In addition to its well-known catalogue, the company produces 12 32-page leaflets with a distribution of 25 million brochures a year. In 2004, Louis was named the best online shop by Computer Bild magazine along with prestigious companies like Amazon, Staples, Ikea and Tchibo. For more information, visit http://www.louis.de/.
About SmarTire Systems Inc.
SmarTire develops and markets proprietary advanced tire pressure monitoring and technology systems for the global automotive and transportation industries. The U.S. government, through the TREAD Act, has legislated that all new passenger vehicles must be equipped with tire monitoring systems beginning with a phased implementation in 2004. SmarTire is capitalizing on the rapidly emerging OEM and aftermarket opportunities. The Company's vision is to become the preeminent provider of wireless sensing and control systems for vehicles worldwide. Incorporated in 1987, SmarTire has offices in North America and Europe.
A comprehensive investment profile regarding SmarTire Systems Inc. may be found at http://www.hawkassociates.com/smartire/profile.htm.
Additional information about SmarTire Systems can be found at http://www.smartire.com. An online investor kit containing SmarTire press releases, SEC filings, current price Level II quotes, interactive Java, stock charts and other useful information for investors can be found at http://www.hawkassociates.com and http://www.hawkmicrocaps.com. Investors may contact Frank Hawkins or Julie Marshall of Hawk Associates at (305) 451-1888, e-mail: info(at)hawkassociates.com.
This release contains various forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended which represent
the company's expectations or beliefs concerning future events of the
company's financial performance. These forward-looking statements are further
qualified by important factors that could cause actual results to differ
materially from those in the forward-looking statements. These factors include
the effect of competitive pricing, the company's dependence on the ability of
third-party manufacturers to produce components on a basis which is cost-
effective to the company, market acceptance of the company's products and the
effects of government regulation. Results actually achieved may differ
materially from expected results included in these statements. The company is
under no obligation to, and expressly disclaims any such obligation to, update
or alter its forward-looking statements, whether as a result of new
information, future events or otherwise.
For further information
Contact: Hawk Associates at (305) 451-1888, Email: info@hawkassociates.com
Source: SmarTire Systems Inc.
Thanks for good laugh this a.m. I need one BHHAHAHAHAHaahaahaa
News..http://biz.yahoo.com/prnews/050718/flm004.html?.v=20
Press Release Source: DNAPrint genomics
DNAPrint genomics' Forensics Technology Featured in Presentation to Florida Sex Crimes Investigators Association
Monday July 18, 7:00 am ET
SARASOTA, Fla., July 18 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAG - News) today announced that the Company's DNAWitness(TM) forensics technology was featured during a presentation at the annual conference of the Florida Sex Crimes Investigators Association annual conference in Orlando.
ADVERTISEMENT
Dr. Matthew Thomas, Ph.D., a scientist at DNAPrint genomics, provided the conference an overview on Thursday, July 14, of how DNAWitness technology can be applied to modern criminal investigations, including investigation of sex crimes.
"DNAWitness is a valuable forensics tool for analyzing DNA recovered at a crime scene because it narrows the search for persons of interest, reducing cost and time in making a potential apprehension," Dr. Thomas said. "DNAWitness is the only testing method available with predictive capability that can identify the percentage of a person's genetic makeup among four possible groups -- Sub-Saharan African, Native American, East Asian and Indo- European. We also have introduced a further expansion of these four genetic groups to include Northern European, Mediterranean, Middle Eastern and Southeast Asian. In addition, recent upgrades in our technology enable DNAPrint genomics to deal with high-volume cases at less cost."
Dr. Thomas noted that another tool in DNAPrint's forensics arsenal is RETINOME(TM), a new genetic test that infers eye (iris) color from DNA. "These are cutting-edge technologies that enable police to identify persons of interest more quickly," he said. "Law enforcement agencies worldwide have utilized DNAWitness to investigate more than 100 crimes and to identify the bodies of missing persons."
Statistical data on sexual assaults in the U.S. vary, depending on how they are categorized. Authorities estimate there are anywhere from 200,000 to 250,000 or more incidents of rape per year, with one in three going unreported. "Serial or aggravated rape in many instances eventually leads to a murder, so catching these perpetrators early, potentially could be a lifesaver," Dr. Thomas said.
"We are pleased that Florida is taking the lead in highlighting the use of DNAWitness in criminal investigations while the rest of the forensics community, for the most part, is still being supported by research dollars to develop technologies that are four to five years out," said DNAPrint President and Chief Executive Officer Richard Gabriel. "Our technology works, and it is available now."
The Florida Sex Crimes Investigators Association was incorporated as a non-profit organization in April 1992 by a small, dedicated group of law enforcement investigators committed to providing low-cost, high-quality training opportunities for its members, and a means of networking and intelligence and information exchange. Today, there are more than 300 members. The website http://www.fscia.org contains information of interest to investigators and prosecutors of sex crimes and child abuse, as well as those who provide services for victims of such crimes. It may be used also as a
resource for the general public who may have questions related to the subject matter.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. ( http://www.dnaprint.com ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests.
Forward-Looking Statements
All statements in this press release that are not historical are forward- looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Company Contact:
Richard Gabriel
CEO and President
941 366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848
Source: DNAPrint genomics
Good morning ann441j.... you're fine and I love U.
We are gonna eat dem grits at Miss Scarlet's yet.
I would like to publicly thank you also... good work!